

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l. (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

### **EXTENSION OF TIME FOR DESPATCH OF CIRCULAR**

The date for despatch of the circular of the Company for the Vitaquest Acquisition has been extended to on or before 30 April 2006 and an application has been made to the Stock Exchange for a waiver from strict compliance with the requirements under Rule 19.38 of the GEM Listing Rules to extend the time for the despatch of the circular.

The Board refers to the announcement dated 3 February 2006 ("Announcement") that the Vitaquest Agreement was entered into between the Purchaser, Vitaquest and the VQ Vendors, which are and the ultimate beneficial owners of which are, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, third parties independent of the Company and its connected persons (as defined in the GEM Listing Rules), whereby the VQ Vendors agreed to sell and the Purchaser agreed to purchase (or to procure another company within the Group to purchase) the entire issued share capital of MOP I Holdings and MOP II Holdings and such number of the membership interests of Vitaquest held by VQ Investments such that upon the VQ Completion, the Purchaser shall own, directly and indirectly (through MOP I Holdings and MOP II Holdings), common membership interests representing an 80% interest in the capital and profits of Vitaquest plus 100% of the Vitaquest Senior Preferred Interests. Capitalized terms used herein have the same meanings as defined in the Announcement, unless the context requires otherwise.

The Vitaquest Acquisition constituted a very substantial acquisition of the Company under the GEM Listing Rules. Pursuant to Rule 19.38 of the GEM Listing Rules, the Company is required to despatch a circular setting out details of the Vitaquest Acquisition to its shareholders within 21 days of the Announcement. Extra time is required to prepare the financial information including the accountants' report on Vitaquest to be contained in the circular. In addition, the Company will announce its results for the year 2005 in mid-March, 2006 and to include the financial information of the Company for the year 2005 in the circular will be more informative and meaningful to the Shareholders, particularly given the size of the Vitaquest Acquisition. The Company has applied to the Stock Exchange for an extension of time for the despatch of the circular to on or before 30 April 2006.

By Order of the Board  
**CK Life Sciences Int'l. (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 23 February 2006

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Dr. Pang Shiu Fun and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its posting and on the website of the Company at [www.ck-lifesciences.com](http://www.ck-lifesciences.com).*